Buy­out buzz cen­ters on a No­var­tis NASH deal for Gen­fit; Syn­thon joins the CD47 club

→ Gen­fit $GN­FT has be­come the tar­get of the lat­est round of M&A ru­mors. StreetInsid­er says that No­var­tis is close to a deal to ac­quire France’s Gen­fit, which has been work­ing on a new drug for NASH, now in Phase III.

→ You can wel­come the Dutch biotech Syn­thon to the ranks of CD47 drug de­vel­op­ers. Syn­thon has li­censed world­wide rights to San­quin’s lead an­ti­bod­ies and IP re­gard­ing the CD47-SIR­Pα path­way to de­vel­op new im­muno-on­col­o­gy treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER